雌激素诱导蛋白pS2表达与ER阳性原发乳腺癌患者辅助内分泌治疗疗效的关系

目的:探讨雌激素诱导蛋白pS2的表达与乳腺癌临床参数和辅助三苯氧胺TAM治疗疗效的关系,明确pS2对辅助内分泌治疗的指导地位。方法:采用免疫组化S蛳P法检测81例ER阳性原发乳腺癌的石蜡切片pS2的表达, 统计学分析其与预后的关系。结果:原发乳腺癌pS2的阳性表达率为66.7 %,其表达与手术年龄(P=0.037)、月经状态(P=0.016)、肿瘤大小(P=0.029)、PR表达情况(P<0.001)密切相关,年龄小于50岁、绝经前、小肿瘤、PR阳性的患者pS2阳性率高。单因素分析和多因素分析均表明pS2是预测OS的独立预后因子。同时pS2对DFS也具有独立预后价值(P=0.023)。结论:pS2是预测ER阳性乳腺癌患者辅助内分泌治疗疗效的独立指标。

Estrogen-induced protein pS2 and response to adjuvant tamoxifen therapy in primary breast cancer with ER-positive

Objective: To investigate the expression of estrogen- induced protein pS2 in breast cancer and it's relation to the clinical manifestations and the response to adjuvant tamoxifen therapy. Methods: Immunostaining for pS2 was performed on 81 paraffin- embedded specimens of ER primary breast cancer patients. Results: Positive expression rate of pS2 in primary breast cancer was 66.7 %. Expression of pS2 was positively correlated with age(P=0.037),menopausal status(P=0.016),tumor size(P=0.029)and PR(P<0.001). pS2 positivity was more frequent in young ,postmenopausal and PR patients as well as small tumors. Both univariate and multivariate analysis demonstrated pS2 had independent influence on OS. pS2 could also provide independent information for DFS(P=0.023). Conclusion: pS2 status can be used as a parameter additional to ER for better refinement of prediction of response to adjuvant tamoxifen therapy.